IM - Moderna to start variant-targeted COVID-19 vaccine trial next week

Moderna ([[MRNA]] -1.1%) is set to begin its first human study for the COVID-19 vaccine candidate targeting a new coronavirus strain as early as next week, The Wall Street Journal reports.According to the details posted on the federal database of clinical trials, the Phase 1 open-label, randomized clinical trial will evaluate the experimental variant vaccine, mRNA-1273.351 alone or in combination with the mRNA-1273 vaccine that is already approved in the U.S.The trial will be conducted in five research sites. Cohort one involving 60 subjects aged 18 years and older will include those who received two vaccinations of mRNA-1273. They will be followed up for 12 weeks after a single intramuscular (IM) injection with mRNA-1273.351.The second cohort involving 150 healthy individuals aged 18 - 55 years will be those who did not receive any COVID-19 vaccine and had no history of COVID-19 infection.Assigned to one of six treatment arms, each will receive 2

For further details see:

Moderna to start variant-targeted COVID-19 vaccine trial next week